A number of recent medical reports have linked high doses of intravenous bisphosphonates given to patients for the treatment of multiple myeloma, breast cancer or other cancers, to a condition […]

A number of recent medical reports have linked high doses of intravenous bisphosphonates given to patients for the treatment of multiple myeloma, breast cancer or other cancers, to a condition […]

Impact Report IMPACT REPORT 2022 – 2023 2022 – 2023 __________   My Story My Story Karen Noel After 25 years as a teacher, many of them working with special […]

Prepared and reviewed by members of the Scientific Advisory Council of Osteoporosis Canada • Dr. Rick Adachi, Rheumatologist, McMaster University • Dr. Robert Josse, Endocrinologist, University of Toronto • Dr. […]

BISPHOSPHONATES The most common family of drugs used to treat osteoporosis Bisphosphonates are the most common family of drugs used to treat osteoporosis. They are part of the group of […]

SUPPORT RESOURCES Booklets, Brochures, Fact Sheets and Inserts English Resources Booklets & Fact Sheets Drug Treatments This four-page fact sheet focuses on medications used to treat osteoporosis. Contains detailed information […]

Romosozumab EVENITY™ (romosozumab injection) Romosozumab, a sclerostin inhibitor, is the first new approach to the treatment of osteoporosis and fracture risk in almost a decade.Romosozumab (EVENITY™) significantly and rapidly (over […]

Board of Directors Jeannette Briggs Chair | Oakville, ON Jeannette has more than 25 years of experience working in the energy sector.  She has held a wide-range of jobs within […]

Denosumab A human monoclonal antibody that prevents RANKL-RANK interaction Denosumab (Bone Metabolism Regulator) Denosumab is a new class of osteoporosis treatment called a human monoclonal antibody that prevents RANKL-RANK interaction […]